Christian Buhlmann, Head of Business Development, Europe and APAC
In the words of The Scottish novelist George McDonald, “to be trusted is a greater compliment than being loved.”
Critical to the success of any sponsor/CRO contract, trust is an indispensable element to allow people to work together in a collaborative manner. While the literature in the realm of contracting and clinical trial management is brimming with articles on dos and don’ts, the industry still lacks the development of high-trust and collaborative working relationships. It’s no longer enough to work with any CRO or trust your drug study to any organization. Evidently, sponsors must rely on experts who are ready to deliver trials on time. This is where PSI CRO is in a class by itself.
More than 25 years into its inception, PSI CRO remains a leading full-service global Contract Research Organization that brings in an impressive track record of enabling sponsors to complete their studies on time. The uniqueness of PSI CRO stems from the trusted relationships it has built with biotech sponsors, with 90 percent of its clientele being repeat customers and referrals. While the CRO market in the APAC region has been deemed as the fastest growing in the world, PSI CRO enables its clients to take advantage of this rapidly growing clinical trial region and deliver their trials on time and within budget. Against this backdrop replete with new technologies and innovations, for a drug to come to market, the CRO has to be aware of the market trends, pharma and biotech landscape, and the regulatory influences in the region. “PSI is actively growing our presence in the APAC market, and we have opened several new offices in the region in the recent years in order to support clients, sites, and trials in the area. We’re excited about this region and passionate about trials in APAC,” says Christian Buhlmann, Head of Business Development, Europe and APAC, PSI CRO. He continues, “PSI CRO is dedicated to on-time delivery and exceptional service.
We are a CRO that builds partnerships, creates lasting value, and, in turn, works to deliver your study on time
We hire experts in the field and are committed to providing high-touch levels of service to our clients and teams to ensure the best success. When others are automating to transform, we are still focused on building partnerships from the ground up to bring a trial to completion.”
With more than 2300 staff across more than 50 countries, the global CRO serves biotechnology sponsors in a wide variety of therapeutic areas, such as Gastroenterology, Oncology, Hematology, Infectious Diseases, Multiple Sclerosis, and Rare Diseases. It also meets the need for various aspects in clinical trial conduct, from regulatory, consulting, biostatistics and data management, marketing, to medical writing, monitoring, and more.
So, how does PSI CRO enable its clients to deliver studies on time?
With its key strength being patient enrollment across phase I to phase IV in multiple therapeutic areas, PSI CRO specializes in on-time delivery coupled with world-class service. The company takes charge of preparing sponsors for success from the very beginning, with each study undergoing a rigorous and customized approach—be it ensuring on-time patient-centric enrollment or crafting patient-centric protocols. From feasibility to site selection, the experts at PSI CRO understand that there is no “one size fits all” in the clinical research industry, and thus work closely with the clients to meet their specific requirements. The privately-owned company operates based on its core values of accountability, teamwork, communication, and staying lean, amongst others. At every level, PSI CRO puts the clients at the forefront of what they do and truly partners with them in their drug development and clinical study journey. “We believe that every patient counts, which means we work tirelessly to enroll patients, connecting with the best sites in the world to do so. We are a CRO that builds partnerships, creates lasting value, and, in turn, works to deliver your study on time,” adds Buhlmann.
Having built a deep network of sites in the APAC region in a short time, partnering with top-notch vendors and teams to support its clients, PSI CRO has no plans of slowing down. “We grow organically to accommodate the needs of our organization in order to best serve our clients and clinical studies. PSI will continue on this growth route as a privately owned, full-service CRO,” concludes Buhlmann.